閆超，博士，南京大學藥理學教授、博士生導師。
基本介紹
- 中文名：閆超
- 畢業院校：美國科羅拉多大學
- 學位/學歷：博士
- 專業方向：毒理學
- 任職院校：南京大學
人物經歷,研究方向,獲獎情況,科研成果,論文,專利,
人物經歷
2003年獲得南京大學生物化學本科學位，2011年獲得美國科羅拉多大學毒理學博士學位。2011年到2015年在科羅拉多大學癌症研究中心從事博士後研究。2015年入選 ;2016年起任南京大學藥理學教授，博士生導師。
研究方向
主要研究方向為小分子抗腫瘤藥物的作用機理和新型靶向藥物的研發;實驗室的工作涉及小分子抗癌藥物的的設計，篩選，合成，藥效，藥理，和毒理學等藥物研發的各個環節。
獲獎情況
科研：
2011年5月 科羅拉多大學最佳博士論文獎(每年只授予一人)
2011年3月 國家優秀自費留學生獎學金
2011年3月 美國毒理學會卡爾史密斯研究獎(全美第一名)
2011年3月 Student Travel Award for the 50th Annual Meeting of the Society of Toxicology
2010年12月 Best Poster Award at the Annual University of Colorado Student Research Forum
2010年9月 Outstanding Student Poster Presentation (1st Place) at the 28th Annual Meeting of the Mountain West Chapter of the Society of Toxicology
2010年9月 Student Travel Award for the 28th Annual Meeting of the Mountain West Chapter of the Society of Toxicology
2008年6月 Best Oral Presentation at the University of Colorado Department of Pharmaceutical Sciences Annual Retreat
2007年8月 Best Poster Award at the University of Colorado Cancer Center Retreat
2003年 國家獎學金二等獎
科研成果
論文
1. Yan C, Jones D, Theodorescu D. Drugging the Ral GTPase. Small GTPases. 2015,6(3):157-9.
2. Yan C, Theodorescu D. One step closer to targeting RAS. Cell Cycle. 2015, 14(3):287-8.
3. Yan C, Liu D, Li L, Wempe MF, Guin S, Khanna M, Meier J, Hoffman B, Owens C, Wysoczynski CL, Nitz MD, Knabe EW, Brautigan DL, Paschal BM, Schwartz MA, Jones DN, Ross D, Meroueh SO, Theodorescu D. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014, 515(7527):443-447.
4. Inman M, Visconti A, Yan C, Siegel D, Ross D, Moody CJ. Antitumour indolequinones: synthesis and activity against human pancreatic cancer cells. Org Biomol Chem. 2014, 12(27):4848-61.
5. Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012, 83(8):1033-40.
6. Yan C, Siegel D, Newsome J, Chilloux A, Moody CJ, Ross D. Antitumor indolequinones induced apoptosis in human pancreatic cancer cells via inhibition of thioredoxin teductase and activation of redox signaling. Mol Pharmacol. 2012, 81(3):401-10.
7. Yan C, Dufour M, Siegel D, Reigan P, Gomez J, Shieh B, Moody CJ, and Ross D. Indolequinone inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Characterization of mechanism of inhibition in both cell-free and cellular systems. Biochemistry. 2011, 50(31):6678-88.
8. Dufour M, Yan C (co-first author), Colucci MA, Jenner M, Oldham NJ, Gomez J, Reigan P, Siegel D, Li Y, De Matteis CI, Ross D, and Moody CJ. Mechanism-based inhibition of quinone reductase 2 (NQO2). Selectivity for NQO2 over NQO1 and structural basis for inhibition. Chembiochem. 2011, 12(8):1203-8.
9. Siegel D, Shieh B, Yan C, Kepa JK, and Ross D. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(Allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. J. Pharmacol. Exp. Ther. 2011, 36(3):874-80.
10. Yan C, Shieh B, Reigan P, Zhang Z, Colucci MA, Chilloux A, Newsome JJ, Siegel D, Chan D, Moody CJ, and Ross D. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target. Molecular Pharmacology. 2009, 76(1):163-72.
11. Yan C, Kepa JK, Siegel D, Stratford IJ, and Ross D. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Molecular Pharmacology. 2008, 74(6):1657-65.
專利
美國專利號62/022946 Anti-cancer compounds targeting Ral GTPases and methods using the same.
